Literature DB >> 19943106

Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.

Abdallah Fayssoil1, Olivier Nardi, David Orlikowski, Djillali Annane.   

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by the absence of dystrophin, a sarcolemmal protein which links the cytoskeleton to the extracellular matrix by interacting with a large number of proteins. Heart failure is a classic complication of this disease. The authors review the pathogenesis and therapeutics of cardiac involvement in DMD.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19943106     DOI： 10.1007/s10741-009-9156-8

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  38 in total

1.  107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

Authors:  K Bushby; F Muntoni; J P Bourke
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

2.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

3.  Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo.

Authors:  Y Kamogawa; S Biro; M Maeda; M Setoguchi; T Hirakawa; H Yoshida; C Tei
Journal:  Cardiovasc Res       Date:  2001-06       Impact factor: 10.787

Review 4.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

Review 5.  Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Authors:  Annemieke Aartsma-Rus; Ivo Fokkema; Jan Verschuuren; Ieke Ginjaar; Judith van Deutekom; Gert-Jan van Ommen; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

6.  Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.

Authors:  Hitoko Ogata; Yuka Ishikawa; Yukitoshi Ishikawa; Ryoji Minami
Journal:  J Cardiol       Date:  2008-10-23       Impact factor: 3.159

Review 7.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.

Authors:  Silvia Brunelli; Clara Sciorati; Giuseppe D'Antona; Anna Innocenzi; Diego Covarello; Beatriz G Galvez; Cristiana Perrotta; Angela Monopoli; Francesca Sanvito; Roberto Bottinelli; Ennio Ongini; Giulio Cossu; Emilio Clementi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

9.  Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.

Authors:  G C Minetti; C Colussi; R Adami; C Serra; C Mozzetta; V Parente; S Fortuni; S Straino; M Sampaolesi; M Di Padova; B Illi; P Gallinari; C Steinkühler; M C Capogrossi; V Sartorelli; R Bottinelli; C Gaetano; P L Puri
Journal:  Nat Med       Date:  2006-09-17       Impact factor: 53.440

Review 10.  Genetic treatments in muscular dystrophies.

Authors:  Francesco Muntoni; Dominic Wells
Journal:  Curr Opin Neurol       Date:  2007-10       Impact factor: 5.710
View more
  43 in total

1.  An unusual case of left ventricular aneurysm in duchenne muscular dystrophy.

Authors:  Xiaozhou Du; Matthew Zeglinski; Nasir Shaikh; Davinder S Jassal
Journal:  Cardiovasc Ultrasound       Date:  2010-11-14       Impact factor: 2.062

Review 2.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

3.  Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice.

Authors:  Xuan Su; Yan Shen; Yue Jin; Meng Jiang; Neal Weintraub; Yaoliang Tang
Journal:  J Vis Exp       Date:  2019-04-10       Impact factor: 1.355

4.  Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca2+ cycling in vivo.

Authors:  Michelle L Law; Kurt W Prins; Megan E Olander; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-17       Impact factor: 4.733

5.  Age-dependent changes in diastolic Ca(2+) and Na(+) concentrations in dystrophic cardiomyopathy: Role of Ca(2+) entry and IP3.

Authors:  Alfredo Mijares; Francisco Altamirano; Juan Kolster; José A Adams; José R López
Journal:  Biochem Biophys Res Commun       Date:  2014-09-19       Impact factor: 3.575

6.  Free-breathing variable flip angle balanced SSFP cardiac cine imaging with reduced SAR at 3T.

Authors:  Subashini Srinivasan; Randall M Kroeker; Simon Gabriel; Adam Plotnik; Sergio R Godinez; Peng Hu; Nancy Halnon; J Paul Finn; Daniel B Ennis
Journal:  Magn Reson Med       Date:  2015-10-28       Impact factor: 4.668

Review 7.  CRISPR Correction of Duchenne Muscular Dystrophy.

Authors:  Yi-Li Min; Rhonda Bassel-Duby; Eric N Olson
Journal:  Annu Rev Med       Date:  2018-10-31       Impact factor: 13.739

8.  Diaphragm degeneration and cardiac structure in mdx mouse: potential clinical implications for Duchenne muscular dystrophy.

Authors:  Isabel Cristina Chagas Barbin; Juliano Alves Pereira; Matheus Bersan Rovere; Drielen de Oliveira Moreira; Maria Julia Marques; Humberto Santo Neto
Journal:  J Anat       Date:  2016-01-29       Impact factor: 2.610

9.  Left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Katherine A James; Jane Gralla; Leslie A Ridall; ThuyQuynh N Do; Angela S Czaja; Peter M Mourani; Emma Ciafaloni; Christopher Cunniff; Jennifer Donnelly; Joyce Oleszek; Shree Pandya; Elinora Price; Michele L Yang; Scott R Auerbach
Journal:  Cardiol Young       Date:  2020-01-22       Impact factor: 1.093

Review 10.  Targeting RNA to treat neuromuscular disease.

Authors:  Francesco Muntoni; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.